中国P站

Obesity; Cancer risk; Adipose tissue inflammation; Gut microbiome; Metabolic health; Epigenetics; Immunotherapy; Bariatric surgery; MAFLD; Carcinogenesis

Introduction

Obesity presents a significant global health challenge, profoundly impacting chronic diseases, including various forms of cancer. This intricate relationship is not merely correlative; it is rooted in a cascade of biological changes initiated by excess adipose tissue. One primary mechanism involves the chronic inflammation and subsequent remodeling of adipose tissue, which together cultivate a pro-tumorigenic microenvironment, significantly influencing the progression and severity of multiple cancer types[1].

The connection between obesity, overall metabolic health, and cancer is inherently multifaceted, with both diet and the gut microbiome emerging as pivotal regulators[2].

Disruptions in normal metabolic pathways, alongside imbalances in the gut's microbial community, are significant contributors to both the initiation and progression of cancer. Recognizing these interdependencies provides invaluable insights for identifying potential targets for preventative strategies and novel therapeutic approaches[2].

Delving deeper, obesity fuels cancer risk through a complex and interconnected network of molecular mechanisms[3].

These mechanisms are diverse, encompassing alterations in crucial hormone levels, persistent chronic inflammation throughout the body, the development of insulin resistance, and significant shifts in growth factor signaling pathways. Collectively, these physiological changes create an internal environment highly conducive to the development and aggressive progression of tumors[3].

Beyond merely increasing the risk of developing cancer, obesity also poses considerable challenges in treatment. It frequently leads to a higher incidence of cancer and contributes to resistance against established therapies[4].

This resistance is largely attributed to systemic changes present in obese patients, which include profound alterations in metabolism, chronic low-grade inflammation that pervades the system, and significant dysfunction within the immune system. All these factors profoundly impact tumor biology and ultimately compromise the efficacy of cancer treatments[4].

Recent scientific inquiry has highlighted epigenetic modifications as a vital mechanistic link connecting obesity and cancer[5].

Environmental factors such as diet, broader lifestyle choices, and obesity-related metabolic changes can directly influence fundamental epigenetic processes. These include changes in DNA methylation patterns, modifications to histone proteins, and altered expression of non-coding RNAs. Such epigenetic reprogramming can activate oncogenic pathways and accelerate the progression of tumors, underscoring a dynamic interplay between genetics and environment[5].

Moreover, obesity fundamentally reconfigures the immune landscape, which can inadvertently promote cancer development and crucially affect how patients respond to immunotherapy[6].

The dysfunction of adipose tissue itself, coupled with systemic chronic inflammation and impaired immune cell functions in obese individuals, collectively contributes to mechanisms of immune evasion by cancer cells and facilitates accelerated tumor growth[6].

This perspective opens avenues for strategies aimed at modulating the immune system in obese cancer patients. The gut microbiome's role is increasingly acknowledged as a critical determinant in obesity-associated cancers, with particular emphasis on colorectal cancer[7].

Dysbiosis, an imbalance in the gut microbial community prevalent in obese individuals, can actively promote inflammation, unfavorably alter host metabolism, and generate genotoxic metabolites. These microbial activities directly contribute to the process of carcinogenesis within the colon and potentially other sites[7].

A robust body of evidence, including systematic reviews and meta-analyses, consistently reinforces the strong statistical association between obesity and an elevated risk of cancer across a broad spectrum of tumor types[8].

This comprehensive epidemiological evidence serves as a powerful mandate for public health authorities to implement effective strategies designed to reduce obesity rates globally, thereby aiming to alleviate the immense burden of cancer[8].

Another significant consequence of obesity, Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), is now understood to considerably increase cancer risk, extending beyond the well-known link to hepatocellular carcinoma[9].

Contemporary reviews of the literature highlight the widespread implications of MAFLD on numerous extrahepatic cancers, pinpointing systemic metabolic dysregulation as a key underlying driver. This suggests MAFLD is not just a liver issue but a systemic cancer risk factor[9].

Crucially, interventions focused on weight loss have demonstrated significant potential in mitigating cancer risk. For individuals grappling with severe obesity, bariatric surgery stands out as a compelling and effective intervention[10].

A thorough systematic review has synthesized robust evidence, confirming that substantial and sustained weight loss achieved through bariatric surgery can notably reduce the incidence of obesity-related cancers, strongly advocating for its role as a powerful preventive strategy in clinical practice[10].

Description

Obesity is a major public health concern, deeply intertwined with an increased risk of developing various cancers. This connection is not superficial; it's driven by fundamental biological processes. One significant factor is the chronic inflammation within adipose tissue, which undergoes structural remodeling in obese individuals. This creates a local microenvironment that actively supports tumor growth and progression, impacting a wide array of cancer types[1]. This intricate interplay emphasizes why targeting adipose tissue health is essential in cancer prevention.

The relationship between obesity, metabolic well-being, and cancer is complex, involving multiple systemic factors. Diet and the composition of the gut microbiome play crucial roles in this dynamic. When metabolic pathways are disrupted, or the delicate balance of the gut microbiome is disturbed, it can significantly contribute to both the start and advancement of cancer[2]. This insight offers promising avenues for interventions focused on dietary adjustments and modulating the gut flora to prevent or treat cancer. Additionally, molecular investigations reveal that obesity fosters cancer risk through an elaborate network of biological mechanisms. These include shifts in hormone levels, persistent inflammation, insulin resistance, and alterations in growth factor signaling, all converging to create an internal milieu conducive to tumor development[3]. Understanding these pathways is key to devising targeted therapeutic strategies.

Beyond initiating cancer, obesity can also influence how tumors behave and respond to treatment. It is frequently associated with a higher incidence of cancer and a reduced efficacy of conventional therapies[4]. This resistance stems from systemic changes common in obese patients, such as altered metabolic profiles, chronic low-grade inflammation throughout the body, and impaired immune system function. These changes directly affect tumor biology, making them more aggressive and less responsive to treatment[4]. Emerging research highlights the role of epigenetic modifications as a crucial link between obesity and cancer. Lifestyle factors, including diet, and metabolic changes induced by obesity can alter DNA methylation, histone modifications, and the expression of non-coding RNAs. These epigenetic changes can activate pathways that promote cancer and accelerate its progression[5]. Therefore, understanding these molecular adjustments provides opportunities for novel preventative and therapeutic strategies.

Furthermore, obesity distinctively shapes the immune system, often in ways that favor cancer. It can create an immune landscape that promotes tumor development and, importantly, can alter how patients respond to immunotherapies[6]. The dysfunction of adipose tissue, persistent inflammation, and changes in immune cell functions in obese individuals contribute to the ability of cancer cells to evade immune detection and destruction, thereby fostering tumor growth[6]. This underscores the need for tailored immunotherapy approaches in obese cancer patients. The gut microbiome is increasingly recognized as a pivotal factor in obesity-associated cancers, with particular emphasis on colorectal cancer. An imbalanced gut microbiome (dysbiosis) in obese individuals can drive inflammation, modify host metabolism, and produce genotoxic compounds that directly contribute to carcinogenesis[7]. These findings emphasize the gut-liver axis and its profound impact on systemic health and cancer risk.

The comprehensive evidence, including systematic reviews and meta-analyses, overwhelmingly confirms a strong link between obesity and an increased risk of cancer across a wide range of tumor types[8]. This robust epidemiological evidence strongly advocates for prioritizing public health initiatives aimed at reducing obesity rates to alleviate the global cancer burden. Moreover, Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), a condition often co-occurring with obesity, has been identified as a significant contributor to cancer risk, extending beyond just liver cancer. Reviews emphasize how MAFLD's systemic metabolic dysregulation drives various extrahepatic cancers, indicating its broad impact on oncogenesis[9]. Encouragingly, interventions that result in substantial weight loss, such as bariatric surgery, offer a compelling strategy to reduce cancer risk in severely obese individuals. A systematic review confirms that the significant weight reduction achieved through surgery effectively mitigates obesity-related cancer incidence, positioning it as a powerful preventive tool[10]. This demonstrates that proactive medical interventions can profoundly alter long-term cancer risk profiles.

Conclusion

Obesity significantly elevates cancer risk through a range of complex biological mechanisms. Adipose tissue inflammation and remodeling create a pro-tumorigenic microenvironment, while altered metabolic health, including diet and gut microbiome disruptions, contribute to cancer initiation and progression. Key molecular pathways involved include altered hormone levels, chronic inflammation, insulin resistance, and aberrant growth factor signaling. These systemic changes in obese individuals not only increase cancer incidence but also contribute to resistance against various therapies, largely due to altered metabolism, persistent low-grade inflammation, and immune dysfunction. Epigenetic modifications, influenced by obesity-related metabolic changes and lifestyle, play a crucial role by altering DNA methylation, histone modifications, and non-coding RNA expression, promoting oncogenic pathways. The immune landscape in obese individuals is also distinct, fostering tumor development and affecting immunotherapy responses through adipose tissue dysfunction and altered immune cell functions. Specific conditions like gut microbiome dysbiosis, particularly linked to colorectal cancer, and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), contribute to broader cancer risks. Robust systematic reviews confirm a strong association between obesity and increased cancer risk across numerous tumor types, highlighting the urgent need for public health strategies. Promisingly, interventions like bariatric surgery, leading to significant weight loss, have shown effectiveness in reducing obesity-related cancer incidence, offering a powerful preventive strategy.

References

1. Alessandra B, Paolo GC, Sara B (2023 Sep 26) .Cells 12:2898.

   , ,

2. Jianbo W, Jennifer EH, John JR (2024 Feb) .Nat Rev Endocrinol 20:83-100.

   , ,

3. Hyungseung K, Xiaoyuan H, Hee YL (2022 Oct 23) .Int J Mol Sci 23:12760.

   , ,

4. Giovanni N, Daniele S, Silvia Z (2021 Feb) .Semin Oncol 48:16-29.

   , ,

5. Jinhui L, Yan G, Zihao Z (2023 Dec) .Semin Cancer Biol 96:1-12.

   , ,

6. Anna MR, Andrea DL, Andrea S (2022 Sep 10) .Int J Mol Sci 23:10486.

   , ,

7. Man AS, Marisol DlF, Chloe H (2021 Dec 9) .Front Cell Infect Microbiol 11:794770.

   , ,

8. Fang Z, Meng J, Si P (2022 Aug 23) .Front Oncol 12:968516.

   , ,

9. Hongmei H, Hui T, Zhi Y (2023 May 10) .Front Oncol 13:1130835.

   , ,

10. Ted DA, Ann MS, Matthew JL (2020 Dec) .Obes Surg 30:4825-4835.

    , ,